Lewisville, Texas-based Orthofix Medical Inc. has appointed Wayne C. Burris to its board of directors and audit and finance committee.
Orthofix Medical Names Finance Exec to BOD
1 min read Premium comments
Secondary#orthofixmedical#wayneburris
Burris retired from Indianapolis, Indiana-based Roche Diagnostics Corporation, a global company that develops diagnostic tests, instruments, and digital solutions for use in healthcare. From 1996 until his retirement in 2019, Burris served as Roche’s senior vice president and chief financial officer. He also led the company as a member of the global Roche diagnostics finance executive committee. Prior to joining Roche, Burris was a senior manager at public accounting firm Price Waterhouse LLP where his clients included global healthcare manufacturers.
Burris is a certified public accountant and a graduate of Indianapolis, Indiana-based Butler University, where he obtained his Bachelor of Science in accounting and finance. The financial executive is involved with community organizations and has played an active role in fostering Indiana’s life sciences community. He was a founding board member of Indianapolis, Indiana-based Indiana Biosciences Research Institute.
Orthofix Chair of the Board Catherine Burzik commented, “We are very pleased that Wayne [Burris] is joining the Orthofix Board of Directors.”
Burzik continued, “His [Burris] strong background in U.S. and international accounting and finance, coupled with his more than 35 years of experience at Roche in various diagnostics, pharma, and orthopedic businesses, makes him well suited to serve on the Orthofix Board as we continue to grow and accelerate our business.”
Founded in 1980, Orthofix is a spine and orthopedics focused medical device company with more than 1,000 worldwide employees. Its products can be found in more than 70 countries across the globe. Its spine business unit focuses on motion preservation, spine fixation, biologics, bone growth therapy, and medical education. Its orthopedics business unit focuses on pediatrics and limb reconstruction, fracture management, foot and ankle, and medical education.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.